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Summary Thirty-four patients with previously treated, advanced, low grade NHL were treated with
Fludarabine, a deamination-resistant analogue of adenosine arabinoside, at a dose of 25 mg m-2 in-
travenously, daily for 5 days (median number of cycles= 3, range 1 -10). Complete remission (CR) was
achieved in six and partial remission (PR) in a further seven. Overall, responses were seen in 11/23 patients
(48%) with follicular lyphoma and in 2/11 (18%) with low grade, diffuse NHL. Fifteen patients with
previously treated CLL and one patient with prolymphocytic leukaemia (PLL) were also treated as above
(median no. of cycles = 3, range 1-6). A partial response was seen in three of the 11 evaluable patients with
CLL and CR was achieved in the patient with PLL. There were four deaths due to infection and 19 further
episodes requiring admission to hospital. No other significant toxicity was reported in a total of 164 cycles of
Fludarabine. This agent is active in advanced low grade lymphoid malignancy. Further studies are required to
assess its role in newly diagnosed patients.
The low grade lymphoid malignancies are characterised by
responsiveness to single agent chemotherapy and by the vir-
tual inevitability of recurrence. Thereafter, although repeated
responses may be achieved, the majority of patients die as a
consequence of the disease. The alkylating agents, chloram-
bucil and cyclophosphamide, when used alone, may induce
response rates of up to 60% in previously untreated patients
with CLL (Knospe et al., 1974; Huguley, 1977; Sawitsky et
al., 1977) but lower response rates with a shorter duration of
remission are the rule for subsequent therapy (Oken & Kap-
lan, 1979; Montserrat et al., 1986). Similarly, in follicular
NHL, response rates to single agent chemotherapy at pre-
sentation and at first and second recurrence remain about
65-70% (Israels et al., 1958; Ezdinli & Stutzman, 1965;
Jones et al., 1973; Anderson et al., 1982) but, thereafter,
therapy becomes rapidly less satisfactory (Gallagher et al.,
1986).
The Kiel classification (Gerard-Marchant et al., 1974)
characterises certain diffuse lymphomas as 'low grade' (lym-
phoplasmacytoid, small cell centrocytic and diffuse
centroblastic/centrocytic). The majority of patients present
with advanced disease; many respond to alkylating agents,
but responses are rarely complete or durable. Hence, fewer
than 20% of those with stage III and IV disease survive for
more than 5 years (Heinz et al., 1981; Swerdlow et al., 1983;
Brittinger et al., 1984; Richards et al., 1989). While respon-
siveness to chlorambucil falls short of that seen in follicular
NHL, the benefits of more intensive therapy in centrocytic
lymphoma have yet to be convincingly demonstrated (Al-
Katib et al., 1984; Meusers et al., 1989). Better therapy is
urgently required.
Fludarabine is a fluorinated analogue of adenosine arabin-
oside (Ara-A), which retains cytotoxicity while being resistant
in the rapid deamination and consequent inactivation which
characterises the metabolism of Ara-A (Dow et al., 1980;
Plunkett et al., 1980; Brockman et al., 1980; Tavoussi &
Avramis, 1986). An active triphosphate metabolite is formed
intracellularly which intereferes with DNA synthesis by
inhibition of DNA polymerase and ribonucleotide reductase
(Huang & Plunkett, 1986). Promise of antitumour activity in
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murine models has been borne out in Phase I and II testing
(Hutton et al., 1984; Spriggs et al., 1986; Champagne et al.,
1987). At a dose of < 125 mg/m2/course, significant activity,
with response rates of 60% and more, has been reported in
CLL and follicular NHL, with some modest benefit in diffuse
low grade lymphoma (Grever et al., 1986; Leiby et al., 1987;
Redman et al., 1988' Hochster & Cassileth, 1990; Keating et
al., 1989a; Puccio et al., 1990). Fludarabine is reported to be
well tolerated at such doses, the toxicity in these studies
being predominantly infective episodes arising from
myelosuppresion.
This report describes further experience of the efficacy and
toxicity of Fludarabine in 50 patients with previously treated
low grade lymphoid malignancy.
Patients and methods
Patients
Thirty four patients with NHL, 15 with CLL, and one with
prolymphocytic leukaemia (PLL) form the basis of this
study. All had received previous chemotherapy. Their clinical
characteristics at the time of treatment with Fludarabine are
shown in Tables I and II. For those with NHL, the Kiel
Classifiction (Gerard-Marchant et al., 1974), and a
modification of the Ann Arbor staging system (Carbone et
al., 1971) were used.
Table I Characteristics of patients with CLL' when treated with
Fludarabine
Men:Women 10:6
Median age 61 years (range 43-81)
Rai stage 2 1
3 4
4 11
Median duration of disease 75 months (6-132)
Median no. of prior regimens 3 (1-8)
No. previously treated with:
anthracyclines 8
splenectomy 3
splenic irradiation 5b
Mean haemoglobin (gdl)-l 10.5 (7.6-13.8)
white cell count (1091)-' 159.5 (6-416)
platelet count (1091)-' 109 (7-355)
aIncluding one patient with prolymphocytic leukaemia. bOne
patient treated on two occasions.
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Table II Characteristics of patients with NHL whc
Fludarabine
Men:Women
Median age
Histology:a Follicular
Lymphoplasmacytoid
Centrocytic, small cell
Lymphocytic
Low grade, unclassified
Median duration of disease
Stage III
IV
Sites of extranodal disease
Bone marrow
Peripheral blood
Liver
Lung
Other
Median no. of prior regimens
No. previously treated with:
Anthracyclines
Splenectomy
aKiel classification.
18:16
54 years
23
4
3
2
2
47 months
7
27
24
5
8
4
3
3
28
4
en treated with stances. In one patient, a dose reduction of 50% was made
for the first two of six cycles because of an initial low
performance status.
(range 32-73) Thirty four patients with NHL received 115 cycles ofFludarabine (mean 3, range 1-10) and 49 cycles were given
to 15 patients with CLL and one patient with PLL (mean 3,
range 1-6). In general, two cycles of therapy were given
beyond the best clinically evaluable response. If no response
was seen after two cycles of therapy, no further Fludarabine
(4-108) was given. Full supportive therapy with antibiotics and blood
products was given as appropriate.
Results
NHL
(1-7)
Response criteria
NHL CR was recorded when there was no clinical or radio-
logical evidence of disease and PR when an estimated reduc-
tion of at least 50% of tumour volume had occurred. Any
lesser response was deemed a treatment failure.
CLL and PLL Complete remission was recorded if the
peripheral blood lymphocyte count was <4.0 x IO' I1, bone
marrow examination showed <30% lymphocytes and there
were no lymph nodes > 0.5 cm or hepatosplenomegaly (Rai
et al., 1975). Partial remission (PR) was recorded if a > 50%
reduction occurred at all sites of disease i.e. circulating lym-
phocytosis, the degree of bone marrow infiltration, lympha-
denopathy and hepatosplenomegaly. Again, a lesser response
was deemed a failure of therapy.
Treatment
Fludarabine was reconstituted in 10 ml of sterile water and
given as a slow intravenous injection. Twenty five mg m2
were given daily for 5 days and repeated every 21-28 days as
dictated by the peripheral blood count and clinical circum-
Response and remission rates according to histology are
shown for the 34 patients in Table III.
The response rate (CR + PR) in follicular lymphoma was
11/23 (48%) including five patients in whom CR was
achieved. The likelihood of response did not correlate with
the number of previous treatments, prior exposure to
anthracyclines (21/23 patients), or treatment of recurrent
rather than refractory disease.
Two responses were seen in the 11 patients with diffuse
histology, one of whom, a 64 year old man with a 5 year
history of stage IV lymphoplasmacytoid lymphoma, entered
CR. Two patients died of progressive lymphoma and another
of a presumed pulmonary embolus. A fourth patient died of
infection (Table IV).
No response was seen in 17 patients, including three of
four patients who received two cycles of Fludarabine as
treatment for 'minimal residual' follicular lymphoma (<10%
bone marrow infiltration (two patients, <2 cm lym-
phadenopathy (one patient)) as the only sites of disease after
conventional therapy. Subsequently, these patients received
cyclophosphamide and total body irradiation supported by
autologous bone marrow transplantation (Rohatiner et al.,
1991).
CLL
Eleven patients are evaluable for response. No complete
remissions were seen. A partial response was observed in
three patients (27%). Three patients died whilst receiving
Table III Response rates by NHL histology (%)
Follicular Lymphopl'd Centrocytic Lymphocytic Unclass
CR 5 (22) 1 (25) _ _ _
PR 6 (26) - - 1 (50) -
Fail 10 (43) 3 (75) 1 (33) 1 (50) 2 (100)
Death 2 (9) - 2 (66)
Total 23 4 3 2 2
Table IV Details of patients dying during therapy with Fludarabine
Duration No. of Prior Karnofljy No. of Flu. Cause of
Age Diagnosis (months) Stage regimens score cycles death Response?
60 NHL 30 3 4 80% 2 Fungal Yes
septicaemia
73 NHL 68 4 4 70% 1 Pulmonary No
embolus?
56 NHL 84 4 5 80% 2 NHL No
92 60% 1 Presumed No
46 NHL 4 4 NHL
57 CLL 47 4 4a 70% 2 Pneumonococcal Yes
sepsis
64 CLL 121 4 6 80% 2 Pulmonary Yes
infection
68 CLL 87 4 4b 40% 1 Septicaemia Yes
alncluding splenectomy. bN
'Including splenectomy. bNot including splenic irradiation x 2.
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treatment; causes of death are shown in Table IV. It is
noteworthy that all three died of infection whilst responding
to Fludarabine. In a further five patients Fludarabine was
ineffective.
Four patients are inevaluable for response, either because
of a coexisting second malignancy (two), or due to death
from unrelated causes (two).
PLL
Complete remission was achieved in a 73 year old man with
prolymphocytic leukaemia, in whomr no response had been
seen to chlorambucil and prednisolone (Smith & Mehta,
1990).
Toxicity
Four patients died of infection while receiving Fludarabine
(Table IV). All were neutropenic at the onset of sepsis. In
patients with CLL, there was nine episodes of infection
requiring admission to hospital and 19 amongst those with
NHL. Other toxicity related to Fludarabine was rare, with
nausea reported on only one occasion. An urticarial rash
occurred in one patient. There were no episodes of central
nervous system or pulmonary toxicity.
Discussion
This report describes experience of the use of Fludarabine as
a single agent in a heavily pretreated group of patients with
advanced disease. Despite this unfavourable setting,
undoubted activity has been demonstrated in both CLL and
follicular NHL, in accordance with other results (Grever et
al., 1986; Leiby et al., 1987; Redman et al., 1988; Keating et
al., 1989a; Hochster & Cassileth, 1990; Puccio et al., 1990).
Since the use of Fludarabine in CLL was first described in
1986 by Grever et al., its promise has been confirmed in a
number of studies in previously treated patients, with re-
sponse rates of over 50% (Keating et al., 1989a; Puccio et
al., 1990). Such response rates already compare favourably
with established programmes of combination therapy such as
CVP, the M2 protocol and CHOP (Kempin et al., 1982;
Montserrat et al., 1986; French Cooperative Group, 1986).
Although the addition of Prednisolone may confer little extra
advantage (Keating et al., 1989b), the attainment of complete
remission reported by Keating et al. (1989a), with the pos-
sibilities of immunophenotypic confirmation (Robertson et
al., 1990) may provide an effective starting point for the
development of treatment programmes that will prolong sur-
vival in CLL.
While the response rate in CLL reported here falls short of
others' experience, direct comparison with a group exhibiting
so many unfavourable features may be misleading. Also, the
number of patients in this study is small and 4/16 patients
died of causes unrelated to Fludarabine.
Prolymphocytic leukaemia is a rare form of leukaemia
sharing many features with CLL but with a universally pro-
gressive course and an unsatisfactory response to therapy.
The only other patient with PLL treated with Fludarabine
reported in the literature also entered complete remission
(Bouroncle et al., 1990). The place of Fludarabine in the
therapy of PLL therefore demands further study.
The role of Fludarabine in the treatment of NHL has, to
date, been less extensively studied. Leiby et al., in 25 patients
with both aggressive and indolent histologies, reported re-
sponses in eight, of whom five had follicular lymphoma
(Leiby et al., 1987). Larger series reported from the M.D.
Anderson Hospital (Redman et al., 1988) and the Eastern
Cooperative Oncology Group (Hochster & Cassileth, 1990)
also suggest response rates of 45-50% in previously treated
low grade lymphoma. This report confirms that Fludarabine
may be of value in the treatment of refractory follicular
lymphoma.
Myelosuppression, with attendant infections, represents the
major toxicity of Fludarabine and demands careful surveil-
lance. The incidence of infective episodes, complicating 17%
of cycles of treatment, is slightly higher than in other series,
but again to some extent reflects the adverse features of the
patient population. The timing of Fludarabine-induced
cytopenia is similar to that of other cytotoxic agents, and
thus similar precautions, with consideration given to the state
of the patient, details of previous therapy, and the degree of
bone marrow infiltration, are essential during monitoring.
Other toxicity is unusual.
In summary, this experience of the use of Fludarabine in
previously treated patients with CLL and low grade NHL
confirms that it is a relatively safe and well tolerated drug
with considerable promise. Further studies will determine
whether this drug will have a significant impact on the
clinical course of these diseases.
We are indebted to the Investigational Drug Branch of the National
Cancer Institute for supplying Fludarabine and to the nursing and
medical staff at the following hospitals: St Bartholomew's, The
Royal Marsden, The Royal Free, Musgrove Park, The Christie,
Chesterfield and North Derbyshire and Oldchurch Hospital. The
authors are pleased to thank Drs S.A.N. Johnson, M. Phillips, R.
Collin, D.S., Lewis, G. Prentice, Professor B. Hofibrand and Profes-
sor D. Crowther for permission to report on patients under their
care. We are grateful for the help of Drs A.G. Stansfeld, J.A.L.
Amess and A.J. Norton.
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